21.26 +0.17 (0.81%)
Pre-Market: 4:03AM EDT
|Bid||0.00 x 900|
|Ask||22.90 x 1000|
|Day's Range||20.94 - 21.49|
|52 Week Range||10.85 - 33.82|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important. Mallinckrodt PLC (NYSE: MNK ) is expected to release Phase 4 interim ...
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.
America's favorite investor doubled down on a bet that this trainwreck isn't as bad as it looks. Should you follow?
Warren Buffett, the billionaire investor and famed Oracle of Omaha, saw the stock portfolio of his Berkshire Hathaway decline by about $2 billion in Q1, according to recent filings with the SEC. The top five positions in Buffett's portfolio represent a whopping two thirds of the entire 13F investment package for the company. As of the end of March, AAPL was the largest portfolio stake for Berkshire Hathaway, accounting for more than 21% of the company's investments, according to its 13F filing.
Teva Pharmaceutical (TEVA) provided an increased guidance for this fiscal year during its first-quarter earnings release on May 3. The company has made an upward revision to its guidance for this fiscal year. Teva reported better-than-expected results in the fiscal first quarter.
Warren Buffett’s Berkshire Hathaway Inc. (NYSE: BRK-A ) (NYSE: BRK-B ) filed its 13F for the first quarter on Tuesday, revealing what changes it made to its portfolio during the period. The company’s equity ...
((Corrects ninth paragraph in May 15 article because of data error, and to show that Berkshire Hathaway is Apple's third-largest shareholder, trailing Vanguard Group and BlackRock, not its second-large) ...
Teva Pharmaceutical (TEVA) has been working towards paying down the high level of debt on its balance sheet. Teva obtained the debt in 2016 to fund the acquisition of Allergan’s (AGN) generic business. At the end of fiscal 2017, Teva had a net debt of $31.5 billion on its balance sheet.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock has been decimated over the years. This morning the stock is rallying on the news that the famed investor Warren Buffett doubled his stake in Teva stock. Wall Street loves to chase Buffett’s investments.
Warren Buffett's Berkshire Hathaway Inc on Tuesday said it has more than doubled its investment in generic drugmaker Teva Pharmaceutical Industries Ltd , and confirmed it has become Apple Inc's second-largest ...
On May 14, Teva (TEVA) stock increased ~5.5% on the news of the expected delay in the FDA approval for rival Perrigo’s (PRGO) generic version of Teva’s asthma inhaler ProAir. On May 14, Teva stock closed at a trading price of $20.38 per share.
Analysts expect AstraZeneca (AZN) to report EPS (earnings per share) of $0.60 on revenue of $5.3 billion in the first quarter, a 2.3% fall compared to its revenue of $5.4 billion during the first quarter of 2017. AstraZeneca’s stock price has risen nearly 7.1% over the last 12 months and ~4.9% year-to-date.
Eli Lilly's (LLY) galcanezumab meets the primary endpoint in a late-stage study evaluating it for the prevention of episodic cluster headache.
The Dow Jones industrials lagged Wednesday's early action as the market defended narrow gains. Teva, Macy's, Boot Barn and China's Tencent set up early leads.
Warren Buffett's seal of approval was helping restructuring drugmaker Teva Pharmaceutical Industries Ltd. Teva's ADRs jumped 4.1% to $21.13 in early trading on Wednesday, May 16, after Buffett's Berkshire Hathaway Inc. Berkshire Hathaway increased its stake in Teva to 40.5 million shares, or about $692.8 million, as of the end of March, up from 18.9 million shares worth a total of $357.7 million as of the end of 2017.
On May 15 after the market closed, Berkshire Hathaway (BRKB) published its holdings at the end of the first quarter as of March 31. According to the company’s SEC filings, it holds 40.5 million Teva Pharmaceutical (TEVA) shares as of March 31—compared to 19 million shares added during the fourth quarter of 2017, according to Berkshire’s filings as of December 31, 2017. At the time, Teva stock rose more than 10% following the news.
In 1Q18, Valeant Pharmaceuticals (VRX) Branded Rx segment generated revenues of $593.0 million, compared to $629.0 million in 1Q17. This reflected ~6.0% growth on a year-over-year (or YoY) basis and an ~1.0% decline quarter-over-quarter.
Berkshire Hathaway doubles its stake in Teva, becomes Apple’s second-largest shareholder and exits its positions in IBM and Graham.
Investor Warren Buffett's company more than doubled its stake in Israeli drugmaker Teva Pharmaceuticals in the first quarter. Berkshire Hathaway Inc. filed an update on its U.S. stock portfolio with the Securities and Exchange Commission on Tuesday. Berkshire said it held 40.5 million Teva shares at the end of March.